Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Binfeng Lu

Showing results (71-80 of 118) with videos related to

Pageof 12
Sort By:
Biomaterials|February 12, 2021
A novel immunochemotherapy based on targeting of cyclooxygenase and induction of immunogenic cell deathHaozhe Huang, Yixian Huang, Yuang Chen, et al.
Acta Biomaterialia|February 1, 2020
Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapyJingjing Sun, Zhuoya Wan, Yichao Chen, et al.
Cancer Immunology Research|September 12, 2020
Tumor-Derived IL33 Promotes Tissue-Resident CD8<sup>+</sup> T Cells and Is Required for Checkpoint Blockade Tumor ImmunotherapyLujun Chen, Runzi Sun, Junchi Xu, et al.
Journal for Immunotherapy of Cancer|January 11, 2019
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolyticsZong Sheng Guo, Binfeng Lu, Zongbi Guo, et al.
Cell Death & Disease|April 17, 2026
Dedifferentiation-driven oncogenic stemness promotes tumor-sustaining adaptability in the intestinal epitheliumKylee Zgeib, Thompson Hui, Simon Garcia, et al.
Oncoimmunology|February 21, 2020
Checkpoint molecules coordinately restrain hyperactivated effector T cells in the tumor microenvironmentMin Yang, Wenwen Du, Lixian Yi, et al.
Cancer Immunology, Immunotherapy : CII|February 4, 2021
IL-36γ-armed oncolytic virus exerts superior efficacy through induction of potent adaptive antitumor immunityMin Yang, Esther Giehl, Chao Feng, et al.
Nature Communications|November 8, 2016
An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapyYichao Chen, Rui Xia, Yixian Huang, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|April 11, 2023
Loss of Protein Kinase D2 Activity Protects Against Bleomycin-Induced Dermal Fibrosis in MiceLiping Chen, Jinjun Zhao, Yapeng Chao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2016
PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against TumorLiangrong Shi, Lujun Chen, Changping Wu, et al.
Pageof 12

Showing results (71-80 of 118) with videos related to

Sort By:
Pageof 12
Biomaterials|February 12, 2021
A novel immunochemotherapy based on targeting of cyclooxygenase and induction of immunogenic cell deathHaozhe Huang, Yixian Huang, Yuang Chen, et al.
Acta Biomaterialia|February 1, 2020
Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapyJingjing Sun, Zhuoya Wan, Yichao Chen, et al.
Cancer Immunology Research|September 12, 2020
Tumor-Derived IL33 Promotes Tissue-Resident CD8<sup>+</sup> T Cells and Is Required for Checkpoint Blockade Tumor ImmunotherapyLujun Chen, Runzi Sun, Junchi Xu, et al.
Journal for Immunotherapy of Cancer|January 11, 2019
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolyticsZong Sheng Guo, Binfeng Lu, Zongbi Guo, et al.
Cell Death & Disease|April 17, 2026
Dedifferentiation-driven oncogenic stemness promotes tumor-sustaining adaptability in the intestinal epitheliumKylee Zgeib, Thompson Hui, Simon Garcia, et al.
Oncoimmunology|February 21, 2020
Checkpoint molecules coordinately restrain hyperactivated effector T cells in the tumor microenvironmentMin Yang, Wenwen Du, Lixian Yi, et al.
Cancer Immunology, Immunotherapy : CII|February 4, 2021
IL-36γ-armed oncolytic virus exerts superior efficacy through induction of potent adaptive antitumor immunityMin Yang, Esther Giehl, Chao Feng, et al.
Nature Communications|November 8, 2016
An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapyYichao Chen, Rui Xia, Yixian Huang, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|April 11, 2023
Loss of Protein Kinase D2 Activity Protects Against Bleomycin-Induced Dermal Fibrosis in MiceLiping Chen, Jinjun Zhao, Yapeng Chao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2016
PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against TumorLiangrong Shi, Lujun Chen, Changping Wu, et al.
Pageof 12